Acuity enhancement

From PsychonautWiki
Jump to navigation Jump to search
Visual acuity enhancement by StingrayZ - This animation serves as a replication of visual acuity enhancement, which is a common psychedelic effect. It demonstrates the general differences between normal vision and acuity enhancement by shifting between the two states. There is also a subtle amount of visual drifting within this replication.

Acuity enhancement is defined as a heightening of the clearness and clarity of vision. This results in the visual details of the external environment becoming sharpened to the point where the edges of objects become perceived as extremely focused, clear, and defined. The experience of acuity enhancement can be likened to bringing a camera or projector lens that was slightly blurry into focus. At its highest level, a person may experience the ability to observe and comprehend their entire visual field simultaneously, including their peripheral vision. This is in contrast to the default sober state where a person is only able to perceive the small area of central vision in detail.[1]

While under the influence of this effect, it is common for people to suddenly notice patterns and details in the environment they may have never previously noticed or appreciated. For example, the complexity and perceived beauty of the visual input often become apparent when looking at sceneries, nature, and everyday textures.

Acuity enhancement is often accompanied by other coinciding effects such as color enhancement and pattern recognition enhancement.[2][3] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA or 3-MeO-PCP.

Image examples

 Caption
DOI
DMT
Pramiracetam
MiPT
2C-I
Piracetam
Experience:337mg DMT fumarate - A Day With DMT
4-AcO-DiPT
1P-LSD
DET
Lisdexamfetamine
25B-NBOH
Bromo-DragonFLY
4-HO-MPT
DPT
Experience:3 drops of cinnamon bark oil/ 5 drops of german chamomile oil/ 2mL of nutmeg oil in lecithin - experiments with nutmeg oil
LSA
Memantine
4-HO-MiPT
Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
4-HO-DiPT
Psilocin
Citicoline
PRO-LAD
Experience: 1.5g Psilocybe Cubensis - Analysis of body and mind
3,4-CTMP
Tree Bark.jpgTree Bark by Chelsea Morgan
MDA
Moss on tree bark.jpgMoss on tree Bark by Chelsea Morgan
TMA-6
Experience:25mg 3-MeO-PCP - Enhanced film experience
Bufotenin
Psilocybin mushrooms
Efavirenz
5-MeO-DiPT
LSD
25C-NBOMe
Experience:BK-2C-B - Various experiences
DOC
2C-P
Allylescaline
1P-ETH-LAD
Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
2C-T-7
4-AcO-MiPT
LSZ
Experience:2.5g Mushrooms + 500mg DMT
Coluracetam
Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
Experience:LSD (120ug) - An Overdose of LSD and Trip into Insanity
Experience:LSA (20 HWBR seeds) – A pleasant adventure with a harsh body load
25C-NBOH
3-MeO-PCP
Proscaline
Experience:300µg LSD - Togetherness and the Silent Dusk
Βk-2C-B
2C-C
ΑMT
Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
MET
5-MeO-DMT
Phenethylamine (compound)
Escaline
25I-NBOMe
Experience:4.5g - The Grand Introduction to Beauty and Fear
5-MeO-DiBF
3-MeO-PCE
Aniracetam
2C-E
4-HO-MET
25D-NBOMe
TMA-2
5-MAPB
Experience:2mg 25C-NBOMe - Experimental trip to test personal limits of NBOMes
1B-LSD
2C-B
4-AcO-MET
4-HO-EPT
Mescaline
3C-E
2-Aminoindane
Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
Experience:40mg - Brothermind and the Forest's Hand
4-HO-DPT
25I-NBOH
PARGY-LAD
Experience:4x 200ug tabs - You do not need to understand
25B-NBOMe
Experience: 15mg 2C-B (oral) - A pleasant low-dose evening with Nexus
25N-NBOMe
Towel.jpgTowel by Chelsea Morgan
4-AcO-DET
MiPLA
DOB
ALD-52
Ayahuasca
MDAI
2C-D
Selective serotonin reuptake inhibitor
5-MeO-MiPT
Experience:20mg - I looked up and saw an angry god-like figure made of clouds glaring down at me
DOM
Experience:3g mimosa / 3g syrian rue - Connecting with my body
Amanita muscaria
Experience:26mg - Stage 3 Trip
MPT
Phenylpiracetam
2C-B-FLY
Experience:800 seeds LSA - My First Trip Ever
Omberacetam
4-HO-DET
Methallylescaline
5-MeO-DALT
Desoxypipradrol
Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
LSM-775
4-AcO-DMT
Oxiracetam
AL-LAD
2C-T-21
ETH-LAD
Ibogaine
2C-T-2

Analysis

It is thought that a fundamental feature of information-processing dysfunction in both hallucinogen-induced states and schizophrenia-spectrum disorders is the inability of these people to screen out, inhibit, filter, or gate irrelevant stimuli and to attend selectively to more important features of the environment.[4][5][6]

The CSTC model of the brain posits that the thalamus plays a key role in controlling or gating external sensory information to the conscious faculties and is thereby fundamentally involved in the regulation of a person's awareness and attention.[7][8][9][10] The interruption of psychedelics to these neural pathways that inhibit the sensory gating systems[11][10] may, therefore, result in an enhanced availability of sensory information which is usually filtered out by these systems. This process is likely also involved in the various visual, tactile, and auditory enhancements which commonly occur when under the influence of a psychedelic experience.

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

Experience reports

Anecdotal reports which describe this effect within our experience index include:

See also

External links

References

  1. Sardegna, Jill; Shelly, Susan; Rutzen, Allan Richard; Scott M Steidl (2002). The Encyclopedia of Blindness and Vision Impairment. Infobase Publishing. p. 253. ISBN 978-0-8160-6623-0. Retrieved 30 November 2014.
  2. Papoutsis, Ioannis; Nikolaou, Panagiota; Stefanidou, Maria; Spiliopoulou, Chara; Athanaselis, Sotiris (2014). "25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers". Forensic Toxicology. 33 (1): 1–11. doi:10.1007/s11419-014-0242-9. ISSN 1860-8965. 
  3. Bersani, Francesco Saverio; Corazza, Ornella; Albano, Gabriella; Valeriani, Giuseppe; Santacroce, Rita; Bolzan Mariotti Posocco, Flaminia; Cinosi, Eduardo; Simonato, Pierluigi; Martinotti, Giovanni; Bersani, Giuseppe; Schifano, Fabrizio (2014). "25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug". BioMed Research International. 2014: 1–6. doi:10.1155/2014/734749. ISSN 2314-6133. 
  4. "Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis". The Journal of Neuropsychiatry and Clinical Neurosciences. 8 (1): 60–66. 1996. doi:10.1176/jnp.8.1.60. ISSN 0895-0172. 
  5. McGhie, Andrew; Chapman, James (1961). "Disorders of attention and perception in early schizophrenia". British Journal of Medical Psychology. 34 (2): 103–116. doi:10.1111/j.2044-8341.1961.tb00936.x. ISSN 0007-1129. 
  6. Vollenweider, F. (2007). "Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research". Pharmacopsychiatry. 31 (S 2): 92–103. doi:10.1055/s-2007-979353. ISSN 0176-3679. 
  7. Goddard, A. W.; Charney, D. S. Toward an integrated neurobiology of panic disorder. J. Clin. Psychiatry 58(suppl. 2):4–11; 1997. https://www.ncbi.nlm.nih.gov/pubmed/9078988
  8. Steriade, M.; Descheˆnes, M. Cellular thalamic mechanisms. In: Bentivoglio, M.; Spreafico, R., eds. Intrathalamic and brainstem-thalamic networks involved in resting and alert state. Amsterdam: Elsevier; 1988:37–62. https://ci.nii.ac.jp/naid/10017402609/en/
  9. Steriade, M; McCormick, D.; Sejnowski, T. (1993). "Thalamocortical oscillations in the sleeping and aroused brain". Science. 262 (5134): 679–685. doi:10.1126/science.8235588. ISSN 0036-8075. 
  10. 10.0 10.1 Vollenweider, Franz X; Geyer, Mark A (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. ISSN 0361-9230. 
  11. Vollenweider F. (1998). Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness. Heffter Rev. Psychedel. Res. 1, 21–32. https://ci.nii.ac.jp/naid/10019112167/